Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
Anti-mesothelin CAR-T cellsBIOLOGICAL
D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
FludarabineDRUG
D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
CyclophosphamideDRUG
D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center | Shanghai | Shanghai Municipality | China |